Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients
Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients
复制标题
DOI：
10.1093/ndt/gfr144
复制
发表时间：
2011-08-01
影响因子：
6.1
通讯作者：
Ortiz, Alberto
中科院分区：
文献类型：
--
作者：
Gonzalez-Parra, Emilio;Luisa Gonzalez-Casaus, Maria;Ortiz, Alberto
背景在慢性肾病（CKD）患者中，磷酸盐负荷的排泄能力受损。甲状旁腺激素（PTH）和成纤维细胞生长因子23（FGF 23）的代偿性增加促进磷酸盐尿。血清FGF 23浓度被认为是过量磷酸盐负荷的早期生物标志物，并且高水平的FGF 23与死亡率增加相关。在本研究中，我们评估了在CKD-3和正常血清磷浓度患者中，用磷结合剂碳酸镧治疗后血浆FGF 23的变化。18例血清磷水平为3a/3b期的白人CKD患者
Background. In chronic kidney disease (CKD) patients, the ability to excrete a phosphate load is impaired. Compensatory increase in parathyroid hormone (PTH) and fibroblast growth factor 23 (FGF23) promote phosphaturia. Serum FGF23 concentration is considered an early biomarker of excess phosphate load and high levels of FGF23 have been associated with increased mortality. In the present study, we have evaluated the changes in plasma FGF23 after treatment with the phosphate binder lanthanum carbonate in patients with CKD-3 and a normal serum phosphate concentration.Methods. Eighteen Caucasian CKD Stage 3a/3b patients with serum phosphate